По вашему запросу найдено документов: 21

Страница 1 из 3

THE POSSIBILITIES OF ART THERAPY AS ONE OF INTEGRATIVE METHODS IN THERAPEUTIC PEDAGOGY
Shmachilina-Tsybenko, SV, Ivanova, OM, Davletshina, GR, Khramova, KV, Chemerilova, IA (2021)
resources of the variety of art therapy methods aimed at integrating and reintegrating a child's personality
Immediate postoperative interventional therapy for neurologic salvage when cerebral thromboembolism complicates carotid endarterectomy
Wang, CL, Zheng, BJ, Gareev, I, Beylerli, O, Gu, Y, Xu, SC, Ji, ZY, Wu, P, Shi, HZ (2021)
salvage therapy for AIS patients after CEA is necessary. In this study,we report three patients in our
Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial
Alexeeva, E, Horneff, G., Dvoryakovskaya, T., Denisova, R., Nikishina, I., Zholobova, E., Malievskiy, V., Santalova, G., Stadler, E., Balykova, L., Spivakovskiy, Y., Kriulin, I., Alshevskaya, A., Moskalev, A. (2021)
+MTX) combination therapy versus step-up MTX monotherapy with ETA added in refractory disease. Methods: A multi
Differential non-coding RNAs expression profiles of invasive and non-invasive pituitary adenomas
Beylerli, O., Khasanov, D., Gareev, I., Valitov, E., Sokhatskii, A., Wang, C., Pavlov, V., Khasanova, G., Ahmad, A. (2021)
Therapy
The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study
Lomakin, NV, Bakirov, BA, Protsenko, DN, Mazurov, VI, Musaev, GH, Moiseeva, OM, Pasechnik, ES, Popov, VV, Smolyarchuk, EA, Gordeev, IG, Gilyarov, MY, Fomina, DS, Seleznev, AI, Linkova, YN, Dokukina, EA, Eremeeva, AV, Pukhtinskaia, PS, Morozova, MA, Zinkina-Orikhan, AV, Lutckii, AA (2021)
with standard of care (SOC). 204 patients received allocated therapy. After the LVL/placebo administration
Фармакоэпидемиологическое исследование COVID-19 в Российской Федерации ЭГИДА-2020
Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020
Pshenichnaya, NY, Kareva, EN, Leneva, IA, Bulgakova, VA, Kravchenko, IE, Nikolaeva, IV, Grekova, AI, Ivanova, AP, Puzyreva, LV, Khasanova, GM, Orlova, SN, Tikhonova, EP, Petrov, VA, Malinin, OV, Kolaeva, NV, Volchkova, EV, Kanshina, NN, Chulanov, VP, Пшеничная, Н.Ю., Карева, Е.Н., Ленева, И.А., Булгакова, В.А., Кравченко, И.Э., Николаева, И.В., Грекова, А.И., Иванова, А.П., Пузырева, Л.В., Хасанова, Г.М., Орлова, С.Н., Тихонова, Е.П., Петров, В.А., Малинин, О.В., Колаева, Н.В., Волчкова, Е.В., Каншина, Н.Н., Чуланов, В.П. (2021)
antiviral therapy
Long non-coding RNAs in oncourology
Gareev, I, Gileva, Y, Dzidzaria, A, Beylerli, O, Pavlov, V, Agaverdiev, M, Mazorov, B, Biganyakov, I, Vardikyan, A, Jin, M, Ahmad, A (2021)
to predict the course of the disease, and plan treatment. Therapy of tumors, especially malignant ones
iASPP protects the heart from ischemia injury by inhibiting p53 expression and cardiomyocyte apoptosis
Yagudin, T, Zhao, Y, Gao, HY, Zhang, Y, Yang, Y, Zhang, XF, Ma, WB, Daba, TM, Ishmetov, V, Kang, K, Yang, BF, Pan, ZW (2021)
infarction in order to facilitate the development of novel therapy. Inhibitor of apoptosis
Применение препарата, содержащего технологически обработанные антитела к каннабиноидному рецептору 1-го типа, для лечения ожирения у взрослых: результаты многоцентрового двойного слепого плацебо-контролируемого рандомизированного клинического исследования
The use of drug based on technologically processed antibodies to endocannabinoid receptor type 1 in the treatment of obesity in adults: results of a multicenter double blind placebo controlled randomized clinical trial
Demidova, TY, Krasil'nikova, EI, Vorob'ev, SV, Morugova, TV, Adasheva, TV, Демидова, Т.Ю., Красильникова, Е.И., Воробьев, С.В., Моругова, Т.В., Адашева, Т.В. (2021)
Survey of diagnostic and treatment practices for multiple sclerosis in Russian Federation in comparison to European data
Boykо, A., Fernández, O., Alifirova, V., Babicheva, N., Bakhtiyarova, K., Volkov, A., Glavinskaya, N., Goncharova, Z., Greshnova, I., Smagina, I., Lashch, N., Inzhinova, A. (2021)
to start with the second line of disease-modifying therapy (DMT), a lower percentage would choose dimethyl

Страница 1 из 3

Google Scholar
OpenDoar

Фасеты

Авторы
Ключевые слова
Год